Lupus & antiphospholipid syndrome
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial
Authors' conclusion
Post hoc analyses of NOBILITY demonstrated that compared with standard-of-care therapy, obinutuzumab treatment resulted in superior preservation of kidney function and prevention of LN flares.
Study context
- Population
- Patients with active lupus nephritis (LN)
- Participants
- 63 vs 62
- Comparison
- Obinutuzumab vs placebo, each with MMF and GC
- Obinutuzumabn = 63
- Placebon = 62reference
- Primary endpoint
- Time to unfavorable kidney outcome:
- Treatment failure
- Doubling of serum creatinine
- Death
Methodological detailsplacebo-controlled
- Placebo-controlled
Primary result
As reported in the abstract
Composite unfavorable kidney outcome
Obinutuzumab reduced the risk of developing the composite kidney outcome
60%
Further findings
CRR on ≤7.5 mg/day prednisone · week 76
P < 0.01
CRR on ≤7.5 mg/day prednisone · week 104 · difference did not achieve significance
P = 0.06
| Outcome | Annualized eGFR slope advantage (ml/min/1.73 m² /year) (95% CI) |
|---|---|
| Chronic eGFR slopeSignificantly slower decline in eGFR with obinutuzumab | 4.1 (0.14–8.08) |
LN flare
- Obinutuzumab reduced the risk of LN flare
- 57%
First estimated glomerular filtration rate (eGFR) decline of 30% or 40%
- Risk reduction, first eGFR decline of 30%
- 80%
- Risk reduction, first eGFR decline of 40%
- 91%
Original publication
Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol. Published 10 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →